Market closed
Black Diamond Therapeutics/$BDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Black Diamond Therapeutics
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Ticker
$BDTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
BDTX Metrics
BasicAdvanced
$90M
-
-$1.27
2.52
-
Price and volume
Market cap
$90M
Beta
2.52
52-week high
$7.66
52-week low
$1.20
Average daily volume
6M
Financial strength
Current ratio
4.918
Quick ratio
4.791
Long term debt to equity
22.551
Total debt to equity
26.639
Management effectiveness
Return on assets (TTM)
-33.71%
Return on equity (TTM)
-69.67%
Valuation
Price to book
1.08
Price to tangible book (TTM)
1.08
Price to free cash flow (TTM)
-1.404
Growth
Earnings per share change (TTM)
-32.49%
3-year earnings per share growth (CAGR)
-28.55%
What the Analysts think about BDTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Black Diamond Therapeutics stock.
BDTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BDTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BDTX News
AllArticlesVideos
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·4 weeks ago
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier
Seeking Alpha·1 month ago
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Black Diamond Therapeutics stock?
Black Diamond Therapeutics (BDTX) has a market cap of $90M as of April 27, 2025.
What is the P/E ratio for Black Diamond Therapeutics stock?
The price to earnings (P/E) ratio for Black Diamond Therapeutics (BDTX) stock is 0 as of April 27, 2025.
Does Black Diamond Therapeutics stock pay dividends?
No, Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next Black Diamond Therapeutics dividend payment date?
Black Diamond Therapeutics (BDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Black Diamond Therapeutics?
Black Diamond Therapeutics (BDTX) has a beta rating of 2.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.